QLGN Average Annual Return Since 2015
Growth of $10,000.00
Without Dividends Reinvested Into QLGN


Also see:
QLGN stock yearly return 2016
QLGN stock yearly return 2017
QLGN stock yearly return 2018
QLGN stock yearly return 2019
QLGN stock yearly return 2020
QLGN stock yearly return 2021
QLGN stock yearly return 2022
QLGN stock yearly return 2023
QLGN YTD return
Compare QLGN average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 06/24/2015
End date: 03/27/2024
Start price/share: $1,240.00
End price/share: $0.40
Dividends collected/share: $0.00
Total return: -99.97%
QLGN Average Annual Return: -60.04%
Starting investment: $10,000.00
Ending investment: $3.22
Years: 8.76


QLGN average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Qualigen Therapeutics is a life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics. Co.'s drug compound QN-302 is being developed to target regulatory regions of cancer genes that down-regulate gene expression in multiple cancer pathways for treatment of G4-targeted tumors. The investigational compounds within Co.'s RAS portfolio are designed to suppress the interaction of endogenous RAS with c-RAF, upstream of the KRAS, HRAS and NRAS effector pathways. Co.'s anticancer drug candidate, QN-247 is aptamer-based to treat a variety of cancer types, including liquid and solid tumors. The QLGN average annual return since 2015 is shown above.

The Average Annual Return on the QLGN average annual return since 2015 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether QLGN average annual return since 2015 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the QLGN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree QLGN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Qualigen Therapeutics (QLGN) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

QNCX Average Annual Return
QTRX Average Annual Return
RANI Average Annual Return
RAPT Average Annual Return
RARE Average Annual Return
RBOT Average Annual Return
RCEL Average Annual Return
RCKT Average Annual Return
RCUS Average Annual Return
RDHL Average Annual Return
More Healthcare companies »

 

QLGN Average Annual Return Since 2015 | www.AverageAnnualReturn.com | Copyright © 2021 - 2024, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.